Income Statement Presentation 2023

Major granted approvals 2022 and 2023 YTD US EU China Vabysmo (faricimab) RG7716 DME Jan 2022 RG7596 Vabysmo (faricimab) RG7716 WAMD RG7446 Jan 2022 Polivy 1L DLBCL May 2022 Tecentriq NSCLC adj RG7446 Tecentriq NSCLC adj March 2022 RG1569 Actemra RG1569 RA SC RG7716 Japan-Chugai Actemra COVID-19 pneumonia Jan 2022 Vabysmo (faricimab) DME June 2022 April 2022 Actemra Lunsumio (mosunetuzumab) Rozlytrek March 2022 Vabysmo (faricimab) RG1569 GCA IV RG7828 3L+ FL RG6268 NTRK+ solid tumors RG7716 WAMD Feb 2022 June 2022 July 2022 Evrysdi Vabysmo (faricimab) Rozlytrek March 2022 Perjeta + Herceptin RG7916 SMA presymptomatic pediatric <2mo RG7716 DME RG6268 ROS1+ NSCLC RG1273 May 2022 Sept 2022 Aug 2022 Xofluza Vabysmo (faricimab) Polivy RG6152 influenza pediatric Aug 2022 Cotellic RG7716 WAMD RG7596 1L DLBCL RG7446 Sept 2022 Jan 2023 Xofluza Polivy RG7421 histiocytosis RG6152 influenza pediatric RG7596 r/r DLBCL RG6013 Oct 2022 Tecentriq Jan 2023 Hemlibra Jan 2023 RG7446 ASPS Dec 2022 RG6013 moderate hemophilia A Jan 2023 RG105 Lunsumio (mosunetuzumab) RG7828 3L+ FL RG7596 Dec 2022 RG1569 Actemra COVID-19 pneumonia Dec 2022 RG7159 HER-2+ CRC March 2022 Tecentriq NSCLC adj May 2022 Hemlibra acquired Hemophilia A June 2022 Rituxan NMOSD June 2022 1L DLBCL Aug 2022 Gazyva 1L CLL Dec 2022 Polivy Status as of February 2, 2023 New Molecular Entity (NME) Additional Indication (Al) Oncology/Hematology Immunology Infectious Diseases Metabolism Neuroscience Ophthalmology Other Roche 82

View entire presentation